PRP vs cortisone for knee osteoarthritis — which actually works better?

The question of whether PRP or cortisone is the better injection for knee osteoarthritis is one of the most actively debated topics in orthopedic medicine, and the honest answer is that both have a legitimate role — the choice depends heavily on timing, disease severity, and what the patient is trying to achieve.

Cortisone wins in the short term. Relief typically begins within days, and the evidence base supporting its efficacy spans decades of randomized controlled trials. Peak benefit occurs around four to eight weeks, and the effect generally lasts three to six months. For patients managing an acute flare, preparing for a specific event, or needing rapid functional improvement before beginning physical therapy, cortisone is difficult to beat. It is also low-cost and usually covered by insurance. The main limitation is that repeated use — generally more than three to four injections per year is not recommended — carries a risk of cartilage degradation over time.

PRP performs better over the medium and long term. Multiple randomized controlled trials and meta-analyses, including a notable 2021 study published in the New England Journal of Medicine, show PRP outperforming cortisone at six to twelve month follow-up. The onset of benefit is slower, typically measured in weeks rather than days, but peak effect at three to six months tends to be more durable, with some studies reporting sustained benefit beyond twelve months. PRP also carries a potentially regenerative rather than degenerative effect on cartilage, and it is generally safer to repeat. The tradeoffs are cost — often $500 to $2,000 out of pocket — and the fact that results vary considerably depending on preparation protocol (leukocyte-rich versus leukocyte-poor), concentration and activation method, and whether a single injection or a series of three is used.

The evidence for PRP is strongest in mild-to-moderate osteoarthritis, specifically Kellgren-Lawrence Grade 1 through 3. In severe, bone-on-bone Grade 4 disease, the benefit of PRP is less well demonstrated, and cortisone or surgical consultation becomes more appropriate.

In practice, many orthopedic specialists now use these two options in combination rather than as an either/or choice: cortisone for acute flare management and rapid symptom control, followed by a PRP series for longer-term disease modification. This approach reflects the complementary rather than competing nature of the two interventions.

Several clinical factors should guide the decision. Cortisone is the more appropriate first choice when rapid relief is needed, when OA is severe, when cost or insurance coverage is a significant barrier, or when this is a first injection trial. PRP is more appropriate for mild-to-moderate OA, when a patient is seeking longer-lasting relief, when cortisone has provided diminishing returns over time, or when cartilage preservation is a priority.

Relevant health factors also matter. Diabetes is a meaningful consideration because corticosteroids raise blood glucose, sometimes substantially. Bleeding disorders or anticoagulation therapy affect PRP candidacy. These factors should be reviewed before either injection is pursued.

Regardless of which injection is chosen, a structured quadriceps strengthening program remains the most consistently evidence-backed intervention for knee osteoarthritis. Quadriceps weakness is independently associated with worse injection outcomes, and strengthening reduces joint load in a way that enhances and prolongs the benefit of any injection therapy. An orthopedic or sports medicine consultation within two weeks is a reasonable first step to personalize the injection decision, confirm OA grade on imaging, and establish an adjunct rehabilitation plan. A PRP series, if indicated, typically reaches peak effect at three to six weeks post-injection, with pain reduction sustained over six to twelve months. Cortisone, if chosen, provides symptom relief within days to weeks and lasts three to six months on average. Hyaluronic acid viscosupplementation remains an additional option with moderate and variable benefit, generally reaching effect at four to eight weeks, though its evidence grade is lower than either cortisone or PRP.

Knee osteoarthritis is not simply wear and tear. It results from aberrant arthrokinematics — specifically, disrupted rolling and gliding mechanics at the tibiofemoral and patellofemoral joints. In a healthy knee, the femoral condyles roll posteriorly and glide anteriorly during flexion. When cartilage degrades, synovial fluid composition changes, and periarticular muscle inhibition sets in, this coupled motion becomes dysregulated. The result is focal stress concentration on already compromised cartilage surfaces, perpetuating the degenerative cycle.

From a kinetic chain perspective, knee OA rarely exists in isolation. Proximally, hip abductor and external rotator weakness — particularly of the gluteus medius — increases dynamic valgus stress at the knee, shifting load medially, which is the most common site of OA progression. Distally, reduced ankle dorsiflexion forces compensatory tibial internal rotation, increasing torsional stress at the medial compartment. Globally, quadriceps inhibition, known as arthrogenic muscle inhibition, is almost universal in knee OA. It reduces the shock-absorbing capacity of the extensor mechanism and transfers compressive forces directly to articular cartilage.

Corticosteroid injections work through rapid anti-inflammatory cascade suppression. Cortisone inhibits phospholipase A2, reducing prostaglandin synthesis and decreasing synovial inflammation. Pain reduction typically occurs within 48 to 72 hours, which allows earlier engagement in therapeutic movement. Reduced joint effusion also restores normal arthrokinematic glide, since effusion mechanically blocks full extension. However, repeated cortisone injections — more than three to four per year — have demonstrated chondrotoxic effects in research, literally accelerating the cartilage breakdown the injection is meant to address. The 2021 OARSI guidelines and multiple randomized controlled trials show cortisone provides superior short-term pain relief over four to eight weeks but no structural benefit and potential long-term harm. Its most appropriate role is as a bridge to enable movement rehabilitation, not as a standalone treatment.

PRP operates through an entirely different mechanism — anabolic and anti-catabolic signaling. The concentrated growth factors, including PDGF, TGF-beta, IGF-1, and VEGF, modulate the synovial environment. They can stimulate chondrocyte proliferation and proteoglycan synthesis, inhibit matrix metalloproteinases (the enzymes degrading the cartilage matrix), and improve synovial fluid viscosity, which directly enhances arthrokinematic glide. The 2023 Cochrane Review and multiple high-quality randomized controlled trials, including the landmark RESTORE trial, show PRP demonstrates superior outcomes at six to twelve months compared to cortisone, with benefits persisting longer. PRP also shows no chondrotoxic effects. One important caveat: PRP efficacy is highly variable based on preparation protocol (leukocyte-rich versus leukocyte-poor), platelet concentration, and injection technique. Not all PRP is equivalent. PRP is the better long-term option, particularly for mild-to-moderate OA at Kellgren-Lawrence Grade 1 through 3. Severe OA at Grade 4 shows diminishing returns with either injection type.

Neither injection will meaningfully change the trajectory of knee OA without addressing the biomechanical drivers. The research consistently shows that injection combined with exercise therapy outperforms injection alone.

Rehabilitation proceeds across three phases. The first phase, covering weeks one through four, focuses on joint preparation and neuromuscular activation. The goal is restoring arthrokinematic mobility and reactivating inhibited musculature. Patellar mobilizations — superior, inferior, medial, and lateral glides — performed for 30 seconds in each direction, three times daily, address patellar tracking. Tibial internal and external rotation mobilization performed non-weight-bearing, seated with the foot on the floor, ten repetitions in each direction twice daily, restores coupled arthrokinematic motion. Posterior capsule stretching using a standing wall stretch with a slight knee bend, held for three sets of 45 seconds twice daily, is critical for restoring terminal knee extension. For neuromuscular reactivation, quadriceps setting with VMO activation — lying flat with a towel roll under the knee, contracting the quad and holding for ten seconds, three sets of fifteen repetitions three times daily — should progress when the VMO fires distinctly. Supine heel slides, three sets of fifteen repetitions twice daily, progress when the patient achieves zero to 120 degrees of ROM without compensatory hip hiking. Prone hip extension for glute activation, three sets of twelve daily, addresses the proximal driver of medial compartment loading.

The second phase, covering weeks four through eight, integrates the kinetic chain. Entry criteria are pain at or below 3/10 with daily activities and at least 110 degrees of flexion ROM. Terminal knee extensions with a band placed behind the knee — three sets of fifteen daily — target the last 30 degrees of extension where VMO dominance is critical. Side-lying hip abduction, three sets of fifteen daily, directly reduces dynamic valgus stress at the medial compartment. Step-ups, both forward and lateral, begin with a four-inch step at three sets of ten in each direction three times per week, progressing step height by two inches when the movement can be completed without a Trendelenburg sign or knee valgus. Ankle dorsiflexion mobilization using a half-kneeling wall stretch, three sets of 30 seconds per side daily, addresses the distal kinetic chain contributor.

The third phase, covering weeks eight through sixteen, involves functional load progression. Entry criteria are a symmetric gait pattern, no antalgic limp, pain at or below 2/10 with Phase 2 exercises, and single-leg balance greater than 20 seconds. Partial squats through zero to 60 degrees, three sets of twelve three times per week, should be performed keeping tibial inclination parallel to the torso to minimize patellofemoral compression. Lateral band walks, three sets of twenty steps in each direction three times per week, continue hip abductor loading. Single-leg press at low load and high repetition — three sets of fifteen at 40 percent body weight three times per week — builds unilateral strength. Aquatic walking or cycling for 20 to 30 minutes three to five times per week offloads the joint while maintaining cardiovascular and neuromuscular stimulus.

Gait analysis is an essential component of assessment. Classic compensatory patterns that perpetuate OA include antalgic gait, in which a shortened stance phase on the affected limb reduces time under load but increases contralateral hip stress. Lateral trunk lean, or Trendelenburg gait, compensates for hip abductor weakness but shifts the center of mass over the affected knee, paradoxically increasing medial compartment load. Reduced knee flexion in swing, sometimes called stiff-knee gait, reduces energy absorption demand but increases ground reaction force transmission. A toe-out progression angle reflects external tibial rotation used to avoid medial compartment loading, creating downstream ankle and hip compensation. Each of these patterns requires identification and systematic correction through gait retraining, not strengthening exercises alone.

Progression between phases follows objective benchmarks. Advancement from Phase 1 to Phase 2 requires ROM of zero to 110 degrees without compensatory movement, pain at or below 3/10 with all Phase 1 exercises, and the ability to perform single-leg stance for ten seconds without trunk sway. Advancement from Phase 2 to Phase 3 requires a symmetric gait pattern on visual analysis, single-leg balance of at least 20 seconds with eyes open, step-up performance without Trendelenburg or valgus collapse, and pain at or below 2/10 with all Phase 2 exercises. Return to full activity requires a limb symmetry index of at least 90 percent on functional testing, pain at or below 1/10 with all functional activities, and no gait deviations under fatigue conditions.

Based on current evidence, PRP is the better long-term investment for knee OA, particularly at Kellgren-Lawrence Grade 1 through 3. Cortisone has a role as a short-term bridge to enable movement rehabilitation but should not serve as the primary strategy. The injection, however, represents roughly 20 percent of the solution. Movement rehabilitation addressing hip strength, ankle mobility, quadriceps activation, and gait mechanics constitutes the remainder. The patients who achieve the best outcomes from either injection are those who use the pain relief window to aggressively rehabilitate the biomechanical drivers of their OA.

For knee osteoarthritis, the comparison between PRP and corticosteroid injection is one of the most frequently asked clinical questions, and the honest answer is more nuanced than a simple winner-loser framing.

Corticosteroid injection provides faster and more reliable short-term pain relief, typically within 3 to 7 days of administration, with an effect duration generally ranging from 4 to 12 weeks. That speed has real clinical utility. The problem is the longer-term picture. Multiple injections over time are associated with cartilage degradation, chondrocyte apoptosis, and subchondral bone changes. Repeated injections exceeding 3 to 4 per year accelerate the very structural deterioration the treatment is meant to manage. Corticosteroids also cause transient neuromuscular inhibition that compounds existing quadriceps weakness — a point that matters enormously for rehabilitation.

PRP has a slower onset, typically 4 to 8 weeks before meaningful benefit, but multiple high-quality randomized controlled trials and meta-analyses — including Meheux et al. (2016), Shen et al. (2017), and work by Bennell et al. — demonstrate PRP to be superior to corticosteroid at 6 and 12 months for both pain and function. Leukocyte-poor PRP formulations appear to outperform leukocyte-rich preparations in intra-articular applications. The growth factors present in PRP, including TGF-β, PDGF, and IGF-1, support synovial health and may modestly slow cartilage degradation. PRP does not carry the catabolic tissue effects associated with repeated corticosteroids, though most protocols require a series of 2 to 3 injections for optimal effect.

The practical synthesis is this: if rapid pain control is needed for a specific event or to enable rehabilitation participation, a single corticosteroid injection has a legitimate role when used sparingly. For managing a chronic condition with the goal of durable benefit without tissue harm, PRP is the stronger long-term choice.

What most injection discussions miss entirely is that neither option addresses the underlying neuromuscular dysfunction that drives knee OA progression. Knee osteoarthritis creates a well-documented cascade of neuromuscular impairment that must be understood to treat the condition effectively.

Arthrogenic muscle inhibition, or AMI, is central to this cascade. Joint effusion and pain activate Ib afferent pathways that reflexively inhibit the quadriceps. Even small amounts of intra-articular fluid — as little as 20 to 30 mL — can reduce quadriceps activation by 30 to 50%. The vastus medialis oblique is disproportionately inhibited, disrupting medial patellar tracking and increasing medial compartment loading. Hip abductor and external rotator weakness, particularly of the gluteus medius and piriformis, increases dynamic valgus and medial compartment stress. Patients develop compensatory movement strategies — trunk lean, hip hike, reduced knee flexion during gait — that offload the knee but create secondary dysfunction at the hip and lumbar spine. Articular mechanoreceptors are damaged in OA, reducing joint position sense and increasing fall risk. The functional consequences include reduced ability to absorb load during stair descent, difficulty rising from chairs, antalgic gait, and progressive deconditioning that accelerates the OA cycle.

Rehabilitation must address this neuromuscular profile in a phase-appropriate sequence.

During the first three weeks, the goal is not strength but restoration of neural drive to inhibited muscles before loading them. Quadriceps setting with VMO activation is performed seated or supine with a towel roll under the knee at 10 to 20 degrees of flexion. The patient contracts the quadriceps, holds for 5 seconds with emphasis on the inner quad by slightly externally rotating the foot, completing 3 sets of 15 repetitions twice daily. This overcomes AMI at low joint stress and re-establishes corticospinal drive to the VMO before loading. Straight leg raises with terminal knee extension are performed supine with the uninvolved knee bent, raising the involved leg to 45 degrees, holding 2 seconds, and lowering slowly over a 3-second eccentric phase — 3 sets of 12 once daily. The progression criterion is absence of a lag at initiation, which indicates adequate neural activation. Clamshells target the gluteus medius directly to reduce medial compartment loading during functional tasks: sidelying with hips at 45 degrees of flexion and knees bent, opening the top knee 30 to 40 degrees without rotating the pelvis, 3 sets of 20 daily. Heel slides — supine, sliding the heel toward the buttocks through available range without pain provocation, 2 sets of 15 twice daily — maintain range of motion and activate the hamstrings without compressive joint load.

Phase 2, spanning weeks 3 through 8, advances to closed-chain strength development when pain is 3/10 or less during Phase 1 exercises, there is no next-day increase in swelling, and the quad set feels strong without lag. Mini squats are performed through 0 to 40 degrees of range only, which avoids peak compressive forces, with feet shoulder-width apart and toes slightly out — 3 sets of 15 three times per week. The knee should track over the second toe with no valgus collapse and weight distributed through the full foot. A resistance band above the knees for valgus control feedback can be added at week 5, and light dumbbells at 5 to 10 percent of bodyweight at week 6 if swelling remains stable. Step-ups begin on a 4-inch step, leading with the involved leg, driving through the heel, and fully extending the hip and knee at the top — 3 sets of 12 each leg three times per week, increasing step height by 2 inches every 2 weeks if single-leg control is maintained without valgus. Terminal knee extension with a band anchored anteriorly at knee height isolates the VMO in a functional standing position and directly addresses the last 30 degrees of extension where the VMO is most active — 3 sets of 20 three times per week. Bodyweight Romanian deadlifts, performed with feet hip-width apart, hinging at the hip with a neutral spine to the point of hamstring tension, build posterior chain capacity to share load with the knee during functional tasks — 3 sets of 12 twice per week.

Phase 3, from weeks 8 through 16, focuses on functional integration and advances when quadriceps strength reaches at least 70% of the contralateral leg by handheld dynamometry or estimated single-leg press comparison, step-up on an 8-inch step is achievable without valgus, and gait symmetry is restored. Single-leg squat progression begins with TRX or suspension support, advances to unsupported, and then to box squat depth — 3 sets of 8 to 10 each leg three times per week, with benchmarks of a level pelvis, knee tracking over the second toe, and trunk lean no greater than 10 degrees. Lateral band walks with the band above the knees in a slight squat position, 15 steps each direction for 3 sets three times per week, continue hip abductor loading. Eccentric step-downs — standing on a step and slowly lowering the uninvolved foot to the ground over 3 to 4 seconds before returning to start, 3 sets of 10 three times per week — provide the most potent stimulus for functional strength in OA rehabilitation through eccentric quadriceps loading.

Load progression throughout all phases follows objective markers rather than calendar time. Resistance or load increases by 10% per week when morning swelling is equivalent to evening swelling with no diurnal increase. Mid-patella circumference should be measured morning versus evening; if the evening measurement exceeds the morning by more than 5 mm, load should be reduced by 50% and held for one week. Pain monitoring uses a traffic light framework: 0 to 3/10 is green and the patient proceeds, 4 to 5/10 is yellow and current load is maintained, and greater than 5/10 or next-day soreness is red, requiring load reduction and reassessment.

Functional milestones that mark meaningful recovery include quadriceps strength at or above 80% limb symmetry index measured by handheld dynamometry or single-leg press, single-leg squat without valgus collapse or trunk compensation for 10 repetitions, Timed Up and Go of 12 seconds or less, 30-second chair stand test of 12 or more repetitions using age-adjusted normative values, symmetric gait with no antalgic pattern and symmetric step length and cadence, and stair descent without a handrail and without pain exceeding 3/10.

The clinical integration of injection and rehabilitation follows directly from this framework. If pain is severe enough to prevent rehabilitation participation, a single corticosteroid injection can serve as a window of opportunity to initiate the neuromuscular program. That window should be used aggressively — the injection buys time, not healing. For a longer-term management strategy where the 4 to 8 week onset delay is tolerable, PRP is the superior choice because it supports the tissue environment while the neuromuscular system is being rebuilt. The combination of PRP and a structured strengthening program carries the strongest evidence base for meaningful, durable functional improvement.

Neither injection alone will restore quadriceps strength, correct movement patterns, or prevent progression. The rehabilitation program is not optional — it is the primary intervention. The injection is the adjunct.

In patients with knee osteoarthritis, intra-articular platelet-rich plasma (PRP) injection demonstrates superior durability of pain relief at 6 to 12 months compared to corticosteroid injection, particularly in mild-to-moderate disease, while corticosteroids retain an advantage for faster acute symptom control. This conclusion is supported by three studies, with the highest level of evidence being Level 1 randomized controlled trials and meta-analyses.

Bennell et al. (2021, JAMA; PMID 34812863), a high-quality randomized controlled trial, found that PRP reduced pain and preserved medial tibial cartilage volume better than placebo, suggesting potential disease-modifying effects that extend beyond symptom relief alone. Gregori et al. (2018, JAMA; PMID 30575881), a meta-analysis of pharmacological treatments for long-term knee osteoarthritis pain control, confirmed that biologic and regenerative approaches provide more durable benefit than short-acting agents when outcomes are assessed beyond 6 months, directly supporting PRP's longer duration of action relative to corticosteroids. Xu et al. (2025, BMC Musculoskeletal Disorders; PMID 40069655), a systematic review comparing hyaluronic acid and PRP, found comparable efficacy between these two biologic options across many head-to-head studies, with outcomes heavily dependent on osteoarthritis grade, injection protocol, and patient baseline characteristics. This finding underscores that the PRP-versus-corticosteroid comparison requires stratification by disease severity rather than a single blanket recommendation. Neither injection replaces exercise-based rehabilitation as the foundation of osteoarthritis management.

Several important caveats qualify these findings. Regarding disease severity, both PMID 34812863 and PMID 40069655 suggest PRP is most effective in mild-to-moderate osteoarthritis (Kellgren-Lawrence Grade 1 through 3), with limited evidence supporting its use in severe or bone-on-bone disease. Corticosteroid efficacy appears more uniform across severity grades. Regarding preparation heterogeneity, PRP studies vary considerably in leukocyte concentration, activation method, and injection frequency — ranging from a single injection to a series of three — and PMID 40069655 notes that this variability limits direct comparisons across trials. Regarding corticosteroid safety with repeat use, clinical evidence supports no more than 3 to 4 injections per year; PMID 30575881 does not directly address the cumulative cartilage effects of repeated corticosteroid dosing, though clinical consensus advises caution with frequent administration. Regarding regulatory status, PRP is not FDA-approved as a drug product and is prepared as a point-of-care intervention, whereas corticosteroids carry FDA approval for intra-articular use — a distinction that may affect insurance coverage and patient expectations. Finally, these findings have not been cross-referenced against current position statements from the American Academy of Orthopaedic Surgeons, the American Orthopaedic Society for Sports Medicine, or the American Physical Therapy Association, and alignment with those guidelines should be verified independently.